Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Wednesday, June 12, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Derivative

PHILADELPHIA - Hemispherix Biopharma handed out big bonuses to its top dogs despite their misrepresentation of trials of its Ampligen drug, which ended so badly it knocked 43% off the share price in one day, shareholders say in a derivative complaint in state court.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.